Please Wait
Applying Filters...
Menu
Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 10Kadcyla

PharmaCompass

01

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

Brand Name : Kadcyla

arrow
German Wound Congress
Not Confirmed

Trastuzumab Emtansine

Main Therapeutic Indication : Oncology

Currency : USD

2019 Revenue in Millions : 1,435

2018 Revenue in Millions : 1,008

Growth (%) : 42

blank

02

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

Brand Name : Kadcyla

arrow
German Wound Congress
Not Confirmed

Trastuzumab Emtansine

Main Therapeutic Indication : Oncology

Currency : USD

2020 Revenue in Millions : 1,944

2019 Revenue in Millions : 1,552

Growth (%) : 25

blank

03

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

Brand Name : Kadcyla

arrow
German Wound Congress
Not Confirmed

Trastuzumab Emtansine

Main Therapeutic Indication : Oncology

Currency : USD

2021 Revenue in Millions : 2,133

2020 Revenue in Millions : 1,850

Growth (%) : 14

blank

04

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

Brand Name : Kadcyla

arrow
German Wound Congress
Not Confirmed

Trastuzumab Emtansine

Main Therapeutic Indication : Oncology

Currency : USD

2022 Revenue in Millions : 2,274

2021 Revenue in Millions : 2,133

Growth (%) : 7

blank

05

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

Brand Name : Kadcyla

arrow
German Wound Congress
Not Confirmed

Trastuzumab Emtansine

Main Therapeutic Indication : Oncology

Currency : USD

2023 Revenue in Millions : 2,281

2022 Revenue in Millions : 2,274

Growth (%) : -5

blank

06

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

07

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

Brand Name : Kadcyla

arrow
German Wound Congress
Not Confirmed

Trastuzumab Emtansine

Main Therapeutic Indication : Oncology

Currency : USD

2015 Revenue in Millions : 541

2014 Revenue in Millions : 777

Growth (%) : 44%

blank

08

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

09

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

10

Brand Name : Kadcyla

Trastuzumab Emtansine

arrow
German Wound Congress
Not Confirmed

Brand Name : Kadcyla

arrow
German Wound Congress
Not Confirmed

Trastuzumab Emtansine

Main Therapeutic Indication : Oncology

Currency : USD

2018 Revenue in Millions : 989

2017 Revenue in Millions : 923

Growth (%) : 7%

blank